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I n this edition of the Brazilian Archives of Endocrinology and Metabolism, a clinical practice guideline and a consensus on thyroid disorders are published. First, the 
Thyroid Department of the Brazilian Society of Endocrinology (SBEM) updates the 
Brazilian consensus on thyroid nodules and differentiated thyroid cancer (1), initially 
published in 2007 (2). Then, for the first time, the Clinical Practice Guideline for the 
Management of Hypothyroidism is published by a task force commissioned by the La-
tin American Thyroid Society (LATS) (3). Those publications are hallmarks for clinical 
practice not only in Latin America, but also worldwide, and serve as guidelines for the 
management of thyroid nodules, differentiated thyroid cancer, and hypothyroidism. 
THE CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF 
HYPOTHYROIDISM
The LATS clinical practice guideline for the management of hypothyroidism is pu-
blished in this issue, just a few months after a similar guideline is published by the 
American Association of Clinical Endocrinologists (AACE) and the American Thyroid 
Association (ATA) (4). Each guideline employs advanced techniques for the selection 
of high-quality and relevant publications, which are graded by levels of evidence (1 
to 5 in the LATS guideline; 1 to 4 in the AACE/ATA guideline). The final recom-
mendations are then based on the levels of evidence provided by the literature, com-
plemented with the experts’ opinions (from A to D in both guidelines). Although 
some fine differences exist in the methodologies employed for outlining the grades of 
recommendations, it is most likely that the final result was not affect by them.
The AACE/ATA guideline has been officially endorsed by several medical associa-
tions worldwide, including the LATS. Therefore, it is expected that both guidelines 
have more similarities than discrepancies. Some of the common key recommendations 
from the LATS and the AACE/ATA clinical practice guidelines are:
For the diagnosis of hypothyroidism, both guidelines acknowledge serum TSH 
level as the first-line diagnostic test. For case-finding, the LATS guideline recommends 
only TSH initially, followed by free T4 if TSH is abnormal and confirmed after 2-3 
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dism, both TSH and free T4 can be measured concom-
itantly. The AACE/ATA guideline is not clear whether 
free T4 should be measured concomitantly, or only after 
altered TSH levels are confirmed. Total serum or free 
T3 are not useful for the diagnosis of hypothyroidism, 
and clinical assessment alone without thyroid function 
tests is not sufficient for the diagnosis of hypothyroi-
dism. However, the LATS guideline does acknowledge 
the importance of certain clinical manifestations that 
increase the likelihood of hypothyroidism. Therefore, 
although thyroid function tests are crucial for the di-
agnosis of hypothyroidism, clinicians should not forget 
the importance of a detailed clinical examination. Also, 
cases of incongruent thyroid hormones levels may oc-
cur, and clinicians should be aware of those situations 
in order to avoid misdiagnosis and mistreatment (5). 
Anti-thyroid peroxidase antibody (TPOAb) mea-
surements are suggested (LATS, grade C) or should be 
considered (AACE/ATA, grade D) to define thyroid 
autoimmunity. In groups at risk for autoimmunity, the 
LATS guideline increases their recommendation grade 
to B. The AACE/ATA guideline also recommends 
measuring TPOAb to predict the onset of overt hypo-
thyroidism in patients with subclinical hypothyroidism, 
and when evaluating patients with recurrent miscar-
riage. Both guidelines acknowledge the importance 
of measuring TPOAb, and their usefulness in defining 
thyroid hormone therapy. Measurement of TSH-re-
ceptor antibodies is discussed only by the AACE/ATA 
guideline: their measurement is recommended in hy-
pothyroid pregnant women with history of previously 
treated Graves’ disease, because they are predictors of 
fetal and neonatal thyrotoxicosis. 
Source of controversy amongst several medical as-
sociations, universal screening is not recommended 
by either guideline; patients with certain clinical con-
ditions, as well as women of fertile age upwards (es-
pecially women over 60 years) and pregnant women, 
should be considered for thyroid testing. Both guide-
lines recommend case-finding rather than screening for 
pregnant women. There is much controversy regarding 
universal screening vs. case-finding of thyroid disorders 
in pregnant women (6), and the screening recommen-
dation might change in the future, when better trials 
evaluating the rates of obstetrical complications and the 
childrens IQ become available. Regarding the elderly, 
the AACE/ATA guideline is more specific and acknow-
ledges that screening for hypothyroidism should be 
considered in patients over the age of 60 years. These 
recommendations differ from the older ATA guidelines 
published in 2000, when frequent early screening was 
recommended beginning at age 35, and every 5 years 
thereafter (7).
For case-finding, according to the AACE/ATA 
guideline, the normal TSH reference range varies ac-
cording to age; if that information is not available, an 
upper limit of normality of 4.12 mU/L should be con-
sidered. In the LATS guideline, the normal reference 
range is 0.45-4.5 mU/L, and a higher cutoff should be 
considered for elderly patients. This recommendation is 
very important for the day-to-day clinical practice, and 
is based on strong level A evidence. In pregnant wo-
men, both guidelines recommend the use of reference 
value ranges specific for each trimester for the diagnosis 
of hypothyroidism. 
Both guidelines recommend against the assessment 
of thyroid function in hospitalized patients, unless there 
is an index suspicion of thyroid dysfunction. However, 
the LATS guideline suggests that, if hypothyroidism 
needs to be ruled out, TSH, T4 and TPOAb should be 
measured concomitantly. 
The use of ultrasound is not discussed in the AACE/
ATA recommendations. The LATS guideline recom-
mends US for patients with hypothyroidism (overt or 
subclinical) and negative antibodies (to diagnose auto-
immune thyroiditis), for patients with subclinical hy-
pothyroidism (to assess the risk of progression to overt 
hypothyroidism), and in patients with abnormal thy-
roid palpation. Whereas ultrasound is a powerful the-
rapeutic tool, its widespread use should be limited in 
order to avoid excessive increases in medical costs and 
in the diagnosis of incidentalomas, which per se require 
additional workup. 
Both guidelines recommend treatment with le-
vothyroxine for patients with serum TSH levels > 10 
mU/L, but the level of recommendation is higher 
for the LATS guideline (A), versus B for the AACE/
ATA guideline. Similarly, both guidelines recommend 
that patients with serum TSH levels above the refer-
ence range (up to 10 mU/L) and normal free T4 (i.e., 
subclinical hypothyroidism) should be treated with le-
vothyroxine if they have increased cardiovascular risk, 
with higher recommendation level in the LATS guide-
line (A). The level of recommendation for treating 
symptomatic middle-aged patients with subclinical hy-
pothyroidism is lower in the LATS than in the AACE/
ATA guideline, as well as for treating patients with 
positive TPOAb and thyroid ultrasonographic findings 
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typical of autoimmune thyroiditis (D). The LATS panel 
recommends against routinely treating elderly patients 
with subclinical hypothyroidism, but acknowledges the 
possibility of treating those patients > 65 years old if the 
aim is to improve cognitive function. 
Treatment of patients with subclinical hypothyroi-
dism remains an area of uncertainty. For instance, it 
has been recently shown that the cardiovascular con-
sequences of subclinical hypothyroidism in elderly may 
be minimal, and that routine treatment may not lead 
to predictable benefit (8). To specifically address the 
management of patients with subclinical hypothyroid-
ism, SBEM has published its own consensus (9). In re-
gards to the normal TSH reference range, that consen-
sus is in concordance with the LATS panel, suggesting 
the normal range between 0.45-4.5 mU/L for healthy 
non-pregnant adults, rather than an age-specific range 
or an upper limit of 4.12 mU/L in the absence of age-
speci fic reference values. Specific to that consensus, 
TSH values up to 20 mU/L are accepted as the up-
per limit for TSH; values beyond 20 mU/L, regardless 
of free T4, would then lead to the diagnosis of overt 
hypothyroi dism. Therefore, this consensus is far more 
conservative is the diagnosis of overt hypothyroidism. 
The diagnosis of hypothyroidism made by the adop-
tion of TSH higher levels up to 20 mU/L (with nor-
mal free T4 values) might lead to the underdiagnosis 
of that condition. However, this approach protects the 
patients against untimely and precocious thyroid hor-
mone replacement that normalizes the levels of TSH; 
it also encourages the clinician to repeat the evaluation 
of thyroid function. The cardiovascular consequences 
of subclinical hypothyroidism are reviewed in the con-
sensus, as are the outcomes following treatment. That 
leads to the recommendation of treating all patients 
with TSH le vels ≥ 10 mU/L, and tailoring therapy in 
patients with lower TSH levels. Table 1 compares the 
recommendations from the LATS and the AACE/ATA 
guidelines, and the SBEM consensus. The recommen-
dations for the treatment of patients with subclinical 
hypothyroi dism is fairly similar across the guidelines, 
but all of them acknowledge that a widely accepted, 
strongly substantiated consensus is far from being 
reached; large, randomized, long-term prospective 
studies evaluating the outcomes of levothyroxine treat-
ment in these patients are needed. 
Levothyroxine is the treatment of choice, and it is 
recommended that the same preparation of levothyrox-
ine is used throughout the treatment, to avoid variations 
in bioequivalence. Combination therapy with levothy-
roxine and triiodothyronine are not recommended 
by the guidelines. The European Thyroid Association 
partly disagrees with that recommendation, and sug-
gests that levothyroxine plus triiodothyronine might be 
considered as an experimental approach in compliant 
patients who have persistent complaints despite serum 
TSH values within the reference range (10). 
The AACE/ATA guideline goes further and re-
commends against the use of iodine supplementation 
in patients from iodine-sufficient areas, desiccated thy-
roid, 3,5,3’-triiodothyroacetic acid (TRIAC), thyroid-
enhancing preparations (such as L-tyrosine), thyromi-
metic preparations (such as Asian Ginseng), selenium, 
and dietary supplements or nutraceuticals for the treat-
ment of hypothyroidism.
Both guidelines recommend treatment with full re-
placement doses (1.6 to 1.8 mcg/kg ideal body weight) 
in healthy young adults. Regarding patients older than 
50-60 years, the AACE/ATA guideline is less conserva-
tive, and recommends initial doses of 50 mcg, instead 
of 12.5-25 mcg/day. For treating subclinical hypo-
thyroidism, the LATS panel recommends a calculated 
initial dose of 1.1 to 1.2 mcg/kg ideal body weight, 
whereas the AACE/ATA panel recommends a fixed 
dose of 25-75 mcg, depending on the degree of TSH 
elevation. Both guidelines agree on the importance of 
the timing of levothyroxine administration, but the 
AACE/ATA guideline is more specific regarding the 
need to take the medication at least 4 hours after the 
last meal, if taken at bedtime. 
Regarding the target TSH levels after levothyrox-
ine is initiated in non-pregnant patients with overt hy-
pothyroidism, the LATS guideline recommends con-
sidering age-dependent target TSH levels: the target 
TSH should be 1-2.5 mU/L for patients < 60 years, 
3-4 mU/L for patients between 60-70 years, and 4-6 
mU/L for those older than 70 years. The AACE/ATA 
guideline recommends that TSH levels are kept within 
the reference range or between 0.45-4.12 mU/L. In 
fact, the AACE/ATA panel discusses the lack of evi-
dence supporting the benefits of targeting specific TSH 
values, which goes against the recommendations of the 
LATS panel. 
In pregnant women with hypothyroidism, the 
AACE/ATA guideline recommends that levothyroxine 
dose should be titrated according to trimester-specific 
TSH reference range; if trimester-specific reference 
range is unavailable, levothyroxine should be titrated 
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to keep TSH levels below 2.5 mU/L, 3 mU/L, and 
3.5 mU/L during the first, second and third trimesters, 
respectively. In the current guideline, the LATS panel 
does not present recommendations regarding the treat-
ment of pregnant women, nor regarding the treatment 
of patients with central hypothyroidism.
For monitoring treatment, the LATS panel re-
commends measuring serum TSH 6-8 weeks after any 
levothyroxine dose change, whereas the AACE/ATA 
panel acknowledges that TSH can be measured sooner, 
4-8 weeks after initiation, of after a dose change. After 
euthyroidism is reached, both panels recommend TSH 
measurements every 6 to 12 months; free T4 mea-
surements have a role only in the early stages of dose 
adjustments, and can be left out after euthyroidism is 
achieved.
Despite some discrepancies, both guidelines are in 
agreement with the most recent evidence from the li-
terature. They are important for guiding clinicians in 
the management of hypothyroidism, but clinical judg-
ment should always prevail. There are still many areas 
of controversy such as the need for broader screening, 
the management of subclinical hypothyroidism, and 
the benefit of designing levothyroxine therapy based 
on age-specific TSH targets. Those areas should be ad-
dressed by large randomized clinical trials.  
THE UPDATE OF THE BRAZILIAN CONSENSUS 
ON THYROID NODULE AND DIFFERENTIATED 
THYROID CANCER
Clinicians can count on many guidelines and consen-
suses addressing the management of thyroid nodules 
(TN) and differentiated thyroid cancer (DTC). In 
2009, the ATA published a revised version of its 2006 
guideline (11). Similarly, SBEM now publishes a revi-
sed version of its own 2007 consensus (1). The degrees 
of recommendation employed by both societies is sli-
ghtly different: the ATA panel presents seven degrees 
of recommendation ranging from “strongly recom-
Analysis of the new guidelines on thyroid disorders
Table 1. Recommendations for the treatment of patients with subclinical hypothyroidism, according to the LATS and the AACE/ATA guidelines, and the 
SBEM consensus
TSH 4.5-10 mU/L TSH ≥ 10 mU/L
LATS AACE/ATA SBEM LATS AACE/ATA SBEM 
Age ≤ 65 years
Without comorbidities No No No Yes Yes Yes
Risk to progression to overt 
hypothyroidism
Consider treatment Consider treatment Consider treatment Yes Yes Yes
Preexisting cardiovascular 
disease or cardiovascular 
risk
Consider treatment 
particularly if TSH ≥ 7 
mU/L
Consider treatment Consider treatment if TSH 
≥ 7 mU/L
Yes Yes Yes
Hypothyroidism symptoms Therapeutic test should be 
considered in middle-aged 
patients
Consider treatment Therapeutic test should be 
considered
Yes Yes Yes
Age > 65 years No Not addressed No Yes Yes Yes
Pregnant women
With positive TPOAb Yes Consider treatment Insufficient data to 
recommend for or against; 
the consensus accepts 
that treatment should be 
initiated
Yes Yes Yes
With negative TPOAb Insufficient data to 
recommend for or against; 
if not treated, monitor 
every 4 weeks up to 
16-20 weeks, and at least 
once between 26-32 
weeks
Consider treatment Insufficient data to 
recommend for or against; 
the consensus accepts 
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mends” to “strongly recommends against”, with a se-
venth recommendation (“neither for nor against”); the 
SBEM panel presents only four degrees of recommen-
dation based on the level of evidence. Therefore, di-
rect comparison of the degrees is not possible, and the 
recommendations should be interpreted with caution.  
The initial biochemistry workup of patients with 
TN is similar for both societies: TSH measurement is 
fundamental. The SBEM panel does not recommend 
the measurement of thyroglobulin and of calcitonin, 
whereas the ATA panel does not have a recommenda-
tion for nor against its measurement. Both panels agree 
that US is fundamental for all patients with thyroid 
nodules, and that computerized tomography, magnetic 
resonance, and FDG-PET are rarely necessary. 
The indication for fine needle aspiration biopsy 
(FNAB) is fairly similar in both guidelines. Functioning 
nodules or purely cystic nodules should not be biop-
sied. Also, regardless of size, both panels recommend 
the biopsy of all non-functioning nodules only if there 
are abnormal cervical lymph nodes or evidence extra-
thyroid invasion. For subcentimeter nodules, in the ab-
sence of high-risk history, both panels agree that the bi-
opsy should be decided upon based on ultrasonographic 
findings. In case of subcentimeter nodules with high-risk 
history, the ATA panel strongly recommends biopsy if 
there are also suspicious ultrasonographic findings, and 
no recommendation is provided if there are no abnor-
mal ultrasonographic findings in subcentimeter nodules 
with high-risk history. The SBEM panel recommends 
the biopsy of subcentimeter nodules if there is high-risk 
OR suspicious findings, but also accepts follow-up with 
US, postponing FNAB when size increases to more than 
1 cm. The recommendations for the biopsy of nodules 
≥ 1 cm are similar in both guidelines, and depend on 
echogenicity, nodule type (solid, cystic, spongiform), 
and ultrasonographic findings. According to the ATA, 
all solid nodules ≥ 1-1.5 cm should be biopsied (> 1 
cm if hypoechoic; ≥ 1-1.5 cm if iso- or hyperechoic), 
whereas SBEM recommends the biopsy of all nodules ≥ 
1 cm if they are hypoechoic; if solid nodules are iso- or 
hyperechoic, they should be biopsied if ≥ 1.5 cm, even 
in the absence of abnormal ultrasonographic findings. 
By restricting FNAB of subcentimeter nodules to specif-
ic cases, both panels miss the diagnosis of some micro-
carcinomas. However, both panels consider that missing 
the diagnosis of microcarcinomas has no clinical impact 
on the patient prognosis, because those tumors have 
slow progression and their cure is not compromised by 
delayed treatment. 
The SBEM panel suggests that FNAB-guided US is 
useful only when initial results are inadequate, whereas 
the ATA panel specifically recommends US guidance for 
FNAB when nodules are non-palpable, predominantly 
cystic, or posteriorly located in the thyroid lobe, and 
in cases when FNAB needs to be repeated for an initial 
non-diagnostic result. There are studies showing that 
US-guided FNAB decreases the rates of inadequate and 
false-negative results, and improves accuracy, sensitivity 
and positive predictive value (12-14). When available 
onsite, FNAB guided by US might be the procedure of 
choice, without incurring in excessive increase in costs.
The approach following FNAB is the same in both 
guidelines, in case of malignant (Bethesda VI), suspec-
ted for malignancy (Bethesda V), follicular neoplasm 
(Bethesda IV), benign (Bethesda II), and inadequate/
non diagnostic results (Bethesda I). In cases of fol-
licular lesion or of atypia or indeterminate significance 
(Bethesda III), the SBEM panel recommends FNAB 
to be repeated in 3-6 months, and indicate surgery 
or follow-up, depending on the degree of suspicion, 
ultrasonographic findings, and nodule size. The ATA 
panel recommends surgery depending on the size of 
the lesion and other risk factors; both panels suggest 
that the use of molecular biomarkers should be con-
sidered, with a strong recommendation by the SBEM 
panel. The use of those biomarkers may become a safe 
and inexpensive alternative to surgery (15), but further 
evaluation is needed. Their use needs to be individually 
assessed, and cost-effectiveness should also be consi-
dered (16). Also, in cases of follicular lesion or of atypia 
or indeterminate significance, FDG-PET is not recom-
mended by the SBEM panel; the ATA panel does not 
have a position on that issue. 
Regarding the management of DTC, both panels 
recommend total thyroidectomy to patients with diag-
nosis of DTC, suggesting that lobectomy may be per-
formed in cases of low-risk papillary carcinoma. The 
recommendations for lymph node dissection are simi-
lar in both panels, as is the recommendation for using 
the AJCC/UICC (TNM) staging system. Prophylactic 
central neck dissection may be considered in cases of 
advances tumors (T3 or T4).
The need for postoperative radioactive (RAI) rem-
nant ablation is source of much controversy amongst 
thyroidologists. RAI ablation is not recommended in 
cases of very low risk (T1N0M0) by both panels, but 
the SBEM panel suggests that the decision to ablate cas-
es of low risk (T1N0M0 with multifocal involvement or 
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T2N0M0) should be made based on the levels of post-
surgical stimulated thyroglobulin (Tg). Even though 
low serum Tg level at the time of ablation is predictive 
of the absence of residual disease, measuring stimulat-
ed Tg post-surgically increases costs and is not widely 
available. Ablation is strongly recommended by both 
panels (levels A/B) only in cases of patients with per-
sistent tumor, metastasis, or high/intermediate risk of 
recurrence. The ATA panel is more detailed in regards 
to ablation recommendations, and may be more use-
ful to guide clinicians. Nevertheless, the degrees of the 
recommendations are not strong, and are mostly based 
on the expert opinions. There is a tendency, however, 
to recommend remnant ablation only to patients with 
high-risk, when the benefits outweigh the risks. There 
are concerns regarding the side effects caused by RAI in 
a population that is relatively young and that has a long 
life expectancy despite the risk of cancer recurrence.   
Both panels strongly recommend ablation following 
recombinant human TSH (rhTSH) stimulation, rather 
than thyroid hormone withdrawal. Clearly there are 
many benefits of rhTSH administration, particularly re-
garding the patient well-being, but it should be noted 
that ablation success rates are the same when compared 
with those achieved by ablation following thyroid hor-
mone withdrawal. In patients with tumor persistence, 
and in children or teenagers, thyroid hormone with-
drawal is still preferred.
Regarding the recommended RAI activity, there is 
a tendency to use lower doses in low-risk patients. The 
SBEM panel is more specific, and recommends 30 mCi 
to low-risk patients; the ATA panel is more flexible, and 
suggests that 30 to 100 mCi may be administered. In 
that regard, the low dose recommended by the SBEM 
panel seems to be more adequate because it is based on 
strong evidence that it lowers the risks and side effects 
associated with RAI, without compromising effective-
ness in low-risk patients (17). Pre-ablation low-iodine 
diet is recommended by both panels.
Before ablation, neither panel recommends per-
forming whole body scan (WBS) at that time, unless 
in the absence of data on surgical extension, or on 
tumor pathology results. There is much controversy 
on whether the pre-dose WBS reduces the efficacy of 
RAI ablation due to the stunning effect, and whether 
it changes the outcomes in patients whose surgical and 
pathology data are known (18). On the other hand, 
post-ablation WBS is recommended for all patients by 
both panels.
The follow-up of patients with DTC submitted to 
surgery and RAI ablation is initially based on neck 
US and measurements of Tg (baseline and stimula-
ted by thyroid hormone withdrawal or rhTSH) and 
TgAb, and subsequent approaches may be considered 
based on their results. In case of patients with Tg > 
1 ng/mL (while on levothyroxine) and normal US, 
the SBEM panel recommends first imaging with tho-
rax computerized tomography or FDG-PET, whilst 
the ATA panel suggests diagnostic WBS. Given the 
fact that diagnostic WBS is performed with lower ac-
tivities of RAI and is less sensitive than therapeutic 
RAI, the SBEM recommendation may be more ade-
quate. The usefulness of the diagnostic WBS, even 
af ter stimulation with rhTSH, is questioned by both 
panels. Regarding the follow-up and management 
of treated patients (including TSH suppression and 
management of patients with metastasis), both panels 
agree on many issues. However, there is some con-
cern on whether clinicians from developing countries 
are able to apply all recommendations in settings of 
limited resources. 
In conclusion, the guidelines addressing the mana-
gement of hypothyroidism and the consensus on thy-
roid nodules and cancer provide valuable information 
for clinicians managing those disorders. From a deci-
sion-making perspective, the presented recommen-
dations should be followed as guidelines rather than 
blindly accepted, and factors inherent to the patients 
and to the clinical setting should be taken into account. 
There are still many unanswered questions that need to 
be addressed in large prospective controlled trials. 
Disclosure: Gilberto Paz-Filho has received consulting fees from 
SANOFI/Genzyme in the past.
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